EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del

Heledd H Jarosz-Griffiths iD, Lindsey Gillgrass, Laura R Caley, Giulia Spoletini iD, Ian J Clifton iD, Christine Etherington, Sinisa Savic, Michael F McDermott, Daniel Peckham iD

PLOS ONE · 31.05.2024 · 19 (5) · e0304555

DOI: 10.1371/journal.pone.0304555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 31.05.2024. Verfasst von Heledd H Jarosz-Griffiths und 8 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Aminophenols, Indoles. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Trust, Leeds Hospital Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation is a key driver in the pathogenesis of cystic fibrosis (CF). We assessed the effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on downregulating systemic and immune cell-derived inflammatory cytokines. We also monitored the impact of ETI therapy on clinical outcome. Adults with CF, heterozygous for F508del (n = 19), were assessed at baseline, one month and three months following ETI therapy, and clinical outcomes were measured, including sweat chloride, lung function, weight, neutrophil count and C-reactive protein (CRP). Cytokine quantifications were measured in serum and following stimulation of peripheral blood mononuclear cells (PBMCs) with lipopolysaccharide (LPS) and adenosine triphosphate and analysed using LEGEND plex ™ Human Inflammation Panel 1 by flow cytometry (n = 19). ASC specks were measured in serum and caspase-1 activity and mRNA levels determined from stimulated PBMCs were determined. Patients remained stable over the study period. ETI therapy resulted in decreased sweat chloride concentrations (p < 0.0001), CRP (p = 0.0112) and neutrophil count (p = 0.0216) and increased percent predicted forced expiratory volume (ppFEV1) (p = 0.0399) from baseline to three months, alongside a trend increase in weight. Three months of ETI significantly decreased IL-18 (p< 0.0011, p < 0.0001), IL-1β (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesAminophenolsIndolesCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAnti-Inflammatory AgentsCytokinesHumansAdultFemaleMalePyrazolesYoung AdultPyridinesLeukocytes, MononuclearC-Reactive ProteinPyrrolesSweatPyrrolidines

Substanzen

BenzodioxolesAminophenolsIndolesCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesivacaftortezacaftorAnti-Inflammatory AgentsCytokineselexacaftor

Autor:innen und Institutionen

  • Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom.
  • Adult Cystic Fibrosis Unit, St James's University Hospital, Leeds, United Kingdom.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.

ORCID-Profile: Heledd H Jarosz-Griffiths, Giulia Spoletini, Ian J Clifton, Daniel Peckham

Förderung

  • Cystic Fibrosis Trust
  • Leeds Hospital Charitable Foundation

Zitieren

APA

Jarosz-Griffiths, H. H., Gillgrass, L., Caley, L. R., Spoletini, G., Clifton, I. J., Etherington, C., Savic, S., McDermott, M. F., & Peckham, D. (2024). Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLOS ONE, 19(5), e0304555. https://doi.org/10.1371/journal.pone.0304555

Vancouver

Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ, Etherington C, et al. Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLOS ONE. 2024;19(5):e0304555. doi:10.1371/journal.pone.0304555

BibTeX
@article{JaroszGriffiths2024,
  author = {Jarosz-Griffiths, Heledd H and Gillgrass, Lindsey and Caley, Laura R and Spoletini, Giulia and Clifton, Ian J and Etherington, Christine and Savic, Sinisa and McDermott, Michael F and Peckham, Daniel},
  title = {Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {5},
  pages = {e0304555},
  doi = {10.1371/journal.pone.0304555}
}
Kostenlos starten →